Answers are grounded in this paper and cite their sources.
Although Helicobacter pylori prevalence is markedly decreased in the last decades, a large endoscopic survey, including 78,985 patients, recently found that such an infection is still present in 15% to 20% of US patients.1 Although a large proportion of infected patients remains asymptomatic, dyspeptic symptoms and/or gastroduodenal lesions, such as peptic ulcer, low-grade gastric lymphoma, and gastric cancer, may occur during the long-life infection, and also an interaction with nonsteroidal anti-inflammatory drugs.2–4 As an effective vaccine is lacking,5 and the efficacy of standard therapies is decreasing,6H. pylori management in clinical practice is still challenging. Therefore, to identify predictors of therapeutic success would seem to be clinically relevant. In past years, different factors have been found to be involved in H. pylori eradication, including host characteristics and bacterial peculiarities (Table 1).TABLE 1: Factors Affecting H. pylori Eradication Therapy SuccessAmong host factors, compliance to therapy plays a major role. It would seem self-evident that an antibiotic therapy cannot exert its whole action when it is not taken for the well-established period and dose. Poor compliance to H. pylori eradication regimen is inversely associated with the probability of therapeutic success. It has been reported that 12% of patients prematurely stopped the eradication therapy as a result of side effects.6 Gastric acid secretion is another factor affecting therapy success. Indeed, the in vitro activity of different antibiotics is deeply reduced or annulled in vivo by the very low pH values encountered in the gastric juice. A small proportion of subjects shows a high basal acid output, despite normal values of the gastrin. In these hypersecretor subjects, who probably have a larger parietal cell mass, lower eradication rates have been reported.7 Eradication therapy success also depends on the metabolism and bioavailability of proton pump inhibitor (PPI), which is genetically determined. Indeed, PPIs are to a large extent metabolized in the liver by the cytochrome P450, isozyme CYP2C19. On the basis of the gene polymorphism, subjects are subgrouped into poor, intermediate, and extensive metabolizers.8 Although some controversial data do exist, standard PPI doses seem to be insufficient in extensive metabolizers to achieve an adequate pH inhibition needed for antibiotic activity in gastric mucosa, with consequent lower eradication rates.9 The efficacy of eradication therapy also depends on gastroduodenal disease. Several studies reported lower H. pylori cure rates in patients with nonulcer dyspepsia (NUD) as compared with those with peptic ulcer disease (PUD).10 Such a difference has been attributed, at least in part, to infection with different H. pylori strains. Indeed, dyspeptic patients are more frequently infected with less virulent (cagA negative; vacA s2 or m2 genotype) and slow-proliferating strains as compared with peptic ulcer patients. These bacterial strains would seem less susceptible toward antibiotics, also resulting in a less marked inflammation as discussed below.11,12 In addition, some studies found a higher prevalence of primary clarithromycin resistance in NUD than in PUD patients, although conflicting data have been reported.13 It is of note that infection recurrence has also been found to be significantly higher in NUD as compared with PUD patients.14H. pylori-related gastritis pattern is another factor affecting bacterial eradication. Indeed, patients with pangastritis achieve lower eradication rates as compared with those with antral gastritis, even when a triple therapy is prolonged to 14 days.15,16 A recent study found that the body mass index significantly affected the H. pylori eradication rate after a standard 7-day triple therapy, lower cure rates being achieved in those patients with a body mass index >25.17 However, this phenomenon was not confirmed when a prolonged 14-day triple therapy regimen was used.16 A lower H. pylori eradication rate has also been shown in adult patients with diabetes as compared with controls,18 although this was not observed in children.19 Finally, ongoing smoking has been consistently reported to negatively affect therapeutic success rate after 7-day triple therapies.20,21 However, this primarily occurred when clarithromycin-amoxicillin was used but not with the clarithromycin-tinidazole combination.22 In addition, smoking did not seem to significantly reduce the H. pylori eradication rate when either 14-day triple therapy or 10-day sequential therapy was used.23 Among bacterial factors, resistance to different antibiotics undeniably plays a major role,6 and the prevalence of H. pylori resistance seems to be increasing worldwide.13 Primary resistance toward clarithromycin has been found to be the main factor hampering the efficacy of standard therapies,24 whereas metronidazole resistance seems to exert a minor impact on the therapeutic outcome.25 It is of note that primary H. pylori resistance toward levofloxacin, an antibiotic generally used in second-line therapy regimens, is also increasing worldwide.26 Another predicting factor is represented by the whole bacterial load in the stomach, high values being associated with lower eradication rates.27–29 Moreover, coccoid forms of H. pylori are not susceptible to the antibiotics, and their presence may have a clinical relevance, due to the potential reactivation of H. pylori in its spiral form after therapy.30,31 Furthermore, some virulence factors significantly affect bacterial susceptibility toward different antibiotics. Indeed, cagA-negative H. pylori seems to be less susceptible to antibiotics as compared with cagA-positive strains. It has been calculated that the eradication rate in patients with cagA-negative strains is 11% [95% confidence interval (CI), 3%-19%; P=0.011] lower than in those with cagA-positive strains.32 Similarly, the presence of vacA s1m1 allele increases bacterial susceptibility as compared with vacA s2m2 allele.11 Shiota et al33 recently identified another H. pylori virulence factor affecting therapy efficacy. In detail, the presence of dupA (duodenal ulcer promoting) gene was found to be an independent predictor of therapy failure [odds ratio (OR): 3.71; 95% CI, 1.07-12.83] at multivariate analysis. However, this association needs to be interpreted with caution for different reasons. First, despite the fact that the OR was statistically significant, the CI was very wide, the lower value (1.07) drastically approaching the indifference. This probably depended on the small sample size (only 26 dupA-positive strains detected among 104 treated patients). Therefore, data need to be confirmed in a larger and prospective series. Second, the mechanism involved in the therapeutic failure in the presence of dupA gene remains unclear, and the hypothesis suggested by the authors would not seem fully convincing. In detail, the authors proposed that patients infected with H. pylori strains harboring the dupA gene may have a higher acid secretion. This was based on the higher gastrin levels found in these patients. However, the plot of gastrin values showed that the higher mean observed in dupA-positive group mainly depended on the data of 2 patients who presented with extremely high gastrin levels (>800 and >1000 pg/mL, respectively). Indeed, gastrin levels (257.2±289.7 vs. 142.8±77.9 pg/mL) were largely overlapping between patients with dupA-positive and dupA-negative strains. The lack of difference in the dupA prevalence between patients with NUD and those with duodenal ulcer, who are acid hypersecretors, further questions the actual role of this factor in the gastric acid output. Third, the study confirmed that primary clarithromycin resistance remains the most important factor affecting the cure rate after standard triple therapy (OR: 7.96; 95% CI, 2.45-25.8). The strength of this association would considerably marginalize the role of dupA gene. In addition, at univariate analysis, the presence of dupA significantly affected the eradication rate only in patients with clarithromycin-resistant strains (28.6% vs. 69%; P=0.04). However, prevalence of dupA gene was significantly lower in clarithromycin-resistant strains, further puzzling data interpretation. Fourth, data in this study, by opening new interpretations of dupA gene mechanism, would seem to be relevant from a microbiological rather than from a clinical perspective. Indeed, to assess dupA gene before therapy in routine clinical practice is impracticable at the same extent of performing bacterial culture.34 According to our opinion, there are at least 2 other clinically relevant findings in Shiota’s study.33 The observed primary clarithromycin resistance rate was as high as 30.9%. This observation would suggest that H. pylori resistance toward such an antibiotic is drastically increasing also in Japan. The other finding is that the eradication rate after standard triple therapies is disappointingly low (<80% at per protocol analysis). By coupling these observations, it seems reasonable to suggest the use of more effective therapies in Japan, such as the sequential or the concomitant therapy regimens.35–37 In conclusion, despite the fact that several potential predicting factors of therapeutic success have been identified, only the prevalence of primary clarithromycin and metronidazole resistance in the general population may be considered to be adequately robust to be applied in clinical practice. Current European guidelines suggest that standard 7-day triple therapy should be prolonged to 14 days where primary clarithromycin resistance is higher than 15% to 20%, also avoiding metronidazole where primary resistance is >40%.38 Nevertheless, on the basis of the available data, it could be reasonable to take into account other factors (Table 1), especially when simultaneously present in the same patient. Patients with NUD, pangastritis, diabetes, smokers, or those with a high bacterial load may be predicted to be at a higher risk of failure with the standard 7-day triple therapy. It is worth noting that unlike bacterial resistance, which may only be indirectly presumed based on data of the general population, these factors are easily available in all patients. However, the real efficacy of a strategy aiming to tailor H. pylori therapy over predicting factors is still largely unknown, and further prospective studies are needed.
No takes yet. Share an insight, caveat, or question.
Zullo et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: